Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 12, 2019 16:15 ET | Source: Anchiano Therapeutics

Anchiano Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results

– Successfully Completed $30.5 million U.S. Initial Public Offering in February 2019 – – Interim Analysis of the Codex Clinical Trial Expected in Fourth Quarter 2019 – CAMBRIDGE, Mass., March 12,...
February 14, 2019 16:40 ET | Source: Anchiano Therapeutics

Anchiano Therapeutics Announces Closing of $30.5 Million Initial Public Offering

CAMBRIDGE, Mass., Feb. 14, 2019 (GLOBE NEWSWIRE) -- Anchiano Therapeutics Ltd. (Nasdaq and TASE: ANCN) (“Anchiano”) today announced that it has closed its initial public offering of 2,652,174 of its...
February 12, 2019 09:15 ET | Source: Anchiano Therapeutics

Anchiano Therapeutics Announces Pricing of $30.5 Million Initial Public Offering

CAMBRIDGE, Mass., Feb. 12, 2019 (GLOBE NEWSWIRE) -- Anchiano Therapeutics Ltd. (Nasdaq and TASE: ANCN) (“Anchiano”) today announced that it has priced its initial public offering of 2,652,174 of its...
January 07, 2019 17:39 ET | Source: Anchiano Therapeutics

Anchiano Therapeutics Announces Filing of F-1 Registration Statement for U.S. Initial Public Offering

CAMBRIDGE, Mass., Jan. 07, 2019 (GLOBE NEWSWIRE) -- Anchiano Therapeutics Ltd. (TASE: ANCN), a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies to...
December 18, 2018 08:30 ET | Source: Anchiano Therapeutics

Anchiano Therapeutics Announces Initiation of Its Pivotal Codex Study of Inodiftagene Vixteplasmid in Patients with Non-Muscle-Invasive Bladder Cancer

CAMBRIDGE, Mass., Dec. 18, 2018 (GLOBE NEWSWIRE) -- Anchiano Therapeutics (TASE: ANCN), a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies to...
November 26, 2018 08:30 ET | Source: Anchiano Therapeutics

Anchiano Therapeutics Announces Appointment of Dr. David Kerstein as New Chief Medical Officer

CAMBRIDGE, Mass., Nov. 26, 2018 (GLOBE NEWSWIRE) -- Anchiano Therapeutics Ltd. (TASE: ANCN), a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies to...
November 19, 2018 08:30 ET | Source: Anchiano Therapeutics

Anchiano Therapeutics Reports Third Quarter 2018 Financial and Operational Results

CAMBRIDGE, Mass., Nov. 19, 2018 (GLOBE NEWSWIRE) -- Anchiano Therapeutics (TASE: ANCN), a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies to...
November 12, 2018 08:30 ET | Source: Anchiano Therapeutics

Anchiano Therapeutics Appoints Dr. Stephen Hoffman and Robert Connelly to Its Board of Directors

Dr. Hoffman joins the Board as Chairman Mr. Connelly is appointed as a Director CAMBRIDGE, Mass., Nov. 12, 2018 (GLOBE NEWSWIRE) -- Anchiano Therapeutics Ltd. (TASE: ANCN), a clinical-stage...
October 31, 2018 08:00 ET | Source: Anchiano Therapeutics

Anchiano Therapeutics Announces Confidential Submission of Draft Registration Statement for U.S. Initial Public Offering

CAMBRIDGE, Mass., Oct. 31, 2018 (GLOBE NEWSWIRE) -- Anchiano Therapeutics Ltd. (TASE: ANCN), a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies to...
September 05, 2018 08:30 ET | Source: Anchiano Therapeutics

Anchiano Therapeutics to Present at the H.C. Wainwright 20th Annual Global Investment Conference

CAMBRIDGE, Mass., Sept. 05, 2018 (GLOBE NEWSWIRE) -- Anchiano Therapeutics (TASE: ANCN), a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies to...